Medical Interventions for Chylothorax and their Impacts on Need for Surgical Intervention and Admission Characteristics: A Multicenter, Retrospective Insight
- 4 January 2021
- journal article
- research article
- Published by Springer Nature in Pediatric Cardiology
- Vol. 42 (3) , 543-553
Abstract
The incidence of chylothorax is reported from 1–9% in pediatric patients undergoing congenital heart surgery. Effective evidenced-based practice is limited for the management of post-operative chylothorax in the pediatric cardiac intensive care unit. The study characterizes the population of pediatric patients with cardiac surgery and chylothorax who eventually require pleurodesis and/or thoracic duct ligation; it also establishes objective data on the impact of various medical interventions. Data were obtained from the Pediatric Health Information System database from 2004–2015. Inclusion criteria for admissions for this study were pediatric admissions, cardiac diagnosis, cardiac surgery, and chylothorax. These data were then divided into two groups: those that did and did not require surgical intervention for chylothorax. Other data points obtained included congenital heart malformation, age, gender, length of stay, billed charges, and inpatient mortality. A total of 3503 pediatric admissions with cardiac surgery and subsequent chylothorax were included. Of these, 236 (9.4%) required surgical intervention for the chylothorax. The following cardiac diagnoses, cardiac surgeries, and comorbidities were associated with increased odds of surgical intervention: d-transposition, arterial switch, mitral valvuloplasty, acute kidney injury, need for dialysis, cardiac arrest, and extracorporeal membrane oxygenation. Statistically significant medical interventions which did have an impact were specific steroids (hydrocortisone, dexamethasone, methylprednisolone) and specific diuretics (furosemide). These were significantly associated with decreased length of stay and costs. Dexamethasone, methylprednisolone, and furosemide were associated with decreased odds for surgical intervention. These analyses offer objective data regarding the effects of interventions for chylothorax in pediatric cardiac surgery admissions. Results from this study seem to indicate that most post-operative chylothoraxes should improve with furosemide, a low-fat diet, and steroids.Keywords
This publication has 23 references indexed in Scilit:
- Evidence-based management of chylothorax in infantsJournal of Pediatric Surgery, 2017
- Lymphodynamics in Congenital Heart DiseaseJACC, 2017
- Octreotide use in post-cardiac surgery chylothorax: a 12-year perspectiveAsian Cardiovascular and Thoracic Annals, 2016
- Report of a case of neonatal chylothorax that responded to long-term octreotide treatment, and review of the literatureThe Turkish Journal of Pediatrics, 2015
- Fat‐Modified Breast Milk Resolves Chylous Pleural Effusion in Infants With Postsurgical Chylothorax but Is Associated With Slow GrowthJournal of Parenteral and Enteral Nutrition, 2015
- Impact of chylothorax on the early post operative outcome after pediatric cardiovascular surgeryJournal of the Saudi Heart Association, 2014
- Incidence and treatment of chylothorax after cardiac surgery in children: Analysis of a large multi-institution databaseThe Journal of Thoracic and Cardiovascular Surgery, 2014
- Utility of a Clinical Practice Guideline in Treatment of Chylothorax in the Postoperative Congenital Heart PatientThe Annals of Thoracic Surgery, 2013
- Chylothorax in children with congenital heart disease: Incidence of thrombosisThrombosis Research, 2013
- Dietary modification of chyle composition in chylothoraxGastroenterology, 1989